Loading organizations...
§ Private Profile · Lausanne, Vaud, Switzerland
Clinical-stage biotech company developing small molecule OGA inhibitors for neurodegenerative diseases, including Alzheimer's and Parkinson's.
Asceneuron is a clinical-stage biopharmaceutical company developing small molecule therapeutics for neurodegenerative diseases, based in Lausanne, Switzerland. The organization focuses on creating oral O-GlcNAcase inhibitors designed to halt the progression of conditions like Alzheimer's disease, Parkinson's disease, and orphan tauopathies by preventing toxic protein aggregation in the brain. To advance its clinical pipeline, the enterprise has secured over $130 million in total funding to date. This financial backing is highlighted by a $100 million oversubscribed Series C financing round in 2024 intended to push its lead asset, ASN51, into Phase 2 clinical development. The recent capital injection was led by Novo Holdings, with additional participation from prominent venture capital firms including EQT Life Sciences and Sofinnova Partners. Asceneuron was founded in 2012 as a spin-off from Merck Serono by co-founders Dirk Beher and Christoph Wiessner.
Asceneuron has raised $133.2M across 3 funding rounds.
Asceneuron has raised $133.2M in total across 3 funding rounds.
Asceneuron has raised $133.2M in total across 3 funding rounds.
Asceneuron's investors include Novo Holdings, 5AM Ventures, Abingworth, Andera Partners, ARCH Venture Partners, EQT Life Sciences, Leaps by Bayer, MRL Ventures Fund, Hakan Goker, M Ventures (Merck), Soffinova Partners, Takeda Ventures.
Asceneuron is a clinical-stage biopharmaceutical company developing oral small-molecule O-GlcNAcase (OGA) inhibitors to treat neurodegenerative diseases by targeting tau protein pathology, including orphan tauopathies like progressive supranuclear palsy (PSP), Alzheimer's disease, and Parkinson's disease.[1][3][4] Its lead candidates are ASN90, licensed to Ferrer Pharmaceuticals for PSP (with orphan drug designations from FDA and EMA), which has completed Phase I studies showing safety and CNS target engagement, and ASN51, a next-generation inhibitor advancing toward Phase 2 in Alzheimer's after Phase I completion and funding from the Alzheimer’s Drug Discovery Foundation.[1][2][4] Asceneuron serves patients with high unmet needs in neurodegeneration, addressing abnormal tau and α-synuclein aggregation to potentially halt disease progression, with demonstrated preclinical efficacy in reducing pathology.[3][4]
The company demonstrates strong growth momentum through clinical advancements, strategic partnerships like the Ferrer license, expansions of its scientific advisory board with neurodegeneration experts, and investor backing from firms including Sofinnova Partners, M Ventures (Merck KGaA), SR One, JJDC, and Kurma Partners.[2][5][6]
Asceneuron was spun out from Merck KGaA’s Merck Serono unit in 2012, founded by Dirk Beher (CEO) and Christoph (likely a key scientific co-founder), leveraging in-house expertise in small-molecule OGA inhibitors to target tau tangle formation in neurodegeneration.[3][5] The idea emerged from recognizing tau's under-explored role compared to amyloid in Alzheimer's, with preclinical data showing OGA inhibition promotes glycosylated tau to prevent hyperphosphorylation and tangles.[1][5] Early traction included joining the Critical Path for Alzheimer’s Disease Consortium, appointing industry veteran Abbas Hussain as Chair, and advancing programs like ASN561 (predecessor to current assets) toward Phase I by 2016, supported by patent applications and plans for Series A funding.[2][5]
Asceneuron rides the wave of tauopathy therapeutics in neurodegeneration, shifting from amyloid-beta disappointments (e.g., recent Alzheimer's trial setbacks) toward tau and α-synuclein as core drivers of neuron loss in Alzheimer's, Parkinson's, and rare tauopathies like PSP.[1][3][5] Timing aligns with surging investment in disease-modifying oral therapies amid aging populations and unmet needs—PSP lacks approved treatments, while Alzheimer's market exceeds $15B potential.[4] Favorable market forces include regulatory orphan incentives, PET imaging advances for target engagement, and consortia like Critical Path accelerating validation.[2][4] By advancing fully brain-penetrant orals with biomarker proof, Asceneuron influences the ecosystem, validating OGA inhibition (competing with players like Alectos) and attracting partnerships that de-risk biotech translation from Merck spinouts.[2][5][6]
Asceneuron is poised for inflection with ASN51's Phase 2 readout in Alzheimer's (post-2024 start) and potential ASN90 expansions, potentially yielding proof-of-concept data by 2026-2027 to enable partnerships or buyouts.[4] Trends like AI-driven biomarker discovery, combo therapies (tau + synuclein), and orphan expansions will shape its path, amplifying impact in a $50B+ neurodegeneration market. Its influence may evolve from clinical pioneer to platform leader if OGA proves broadly disease-modifying, validating its tau-targeting bet from the 2012 Merck origins.[1][3][5]
Asceneuron has raised $133.2M across 3 funding rounds. Most recently, it raised $100.0M Series C in July 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jul 1, 2024 | $100M Series C | Novo Holdings | 5AM Ventures, Abingworth, Andera Partners, ARCH Venture Partners, EQT Life Sciences, Leaps BY Bayer, MRL Ventures Fund, Hakan Goker, M Ventures, Soffinova Partners, Takeda Ventures, Versant Ventures | Announced |
| Mar 12, 2021 | $2.2M Grant | — | — | Announced |
| Sep 1, 2015 | $31M Series A | Soffinova Partners | 5AM Ventures, Abingworth, Andera Partners, ARCH Venture Partners, EQT Life Sciences, Leaps BY Bayer, MRL Ventures Fund, M Ventures, Takeda Ventures, Versant Ventures | Announced |